Aspirin for primary prevention of atherosclerotic cardiovascular events
| Autor: | Aldo L. Schenone, A. Michael Lincoff |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Aspirin business.industry MEDLINE General Medicine Atherosclerosis medicine.disease Primary Prevention 03 medical and health sciences 0302 clinical medicine Cardiovascular Diseases Heart Disease Risk Factors Primary prevention Internal medicine Diabetes mellitus medicine Humans In patient 030212 general & internal medicine Intermediate risk business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Cleveland Clinic Journal of Medicine. 87:300-311 |
| ISSN: | 1939-2869 0891-1150 |
| Popis: | Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|